Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Evidence based atrial fibrillation (AF) management guidelines recommend oral anticoagulation (OAC) for patients with atrial fibrillation at moderate to high risk of stroke and without contraindications regardless of type of atrial fibrillation. The literature suggests a misconception about stroke risk in relation to type of AFresulting in a significant proportion of patients with paroxysmal AF not receiving prophylactic anticoagulation. It is unclear if this misconception persists in clinical practice. Using UK data from a global AF registry we investigated the use of antithrombotic therapy according to CHADS2score and type of AF.

Original publication




Journal article



Publication Date



16 Suppl 3